Home › Biotechnology and Pharmaceuticals › Island Pharmaceuticals (ASX:ILA)

Island advances Galidesivir toward pivotal Marburg testing

Biotechnology and Pharmaceuticals By Victor Sage 4 min read

Island Pharmaceuticals is moving Galidesivir into a decisive sequence of Marburg animal studies after the FDA confirmed an Animal Rule pathway for the antiviral. The company also expects to generate prospective human data through an approved Uganda Ebola program, although approval, funding and commercial outcomes remain unresolved.

  • Marburg dose-response study expected to begin in early December 2026
  • Company reported 94% survival in a treated Marburg primate model versus 0% for placebo
  • FDA confirmed the Animal Rule pathway and advised Galidesivir may qualify for a Tropical Disease Priority Review Voucher
  • Uganda MEURI program could generate prospective human safety and virological data in 2027
  • Cash at 30 June 2026 was $7.83 million, with no debt reported

Galidesivir reaches its next Marburg decision point

Island Pharmaceuticals Limited (ASX:ILA) is preparing to start a blinded Marburg dose-response study in early December, putting the company’s lead antiviral into the next practical test of whether its animal data can support a development dose. The study is intended to assess survival, dose response, pharmacokinetics and viral burden, but Island explicitly describes it as a decision-making milestone rather than a registration study.

“Marburg NHP Survival”Caption and image © Island Pharmaceuticals Limited. From “Investor webinar presentation”, 17 Nov 2026.

The company’s presentation points to a reported 94% survival rate in Marburg-infected non-human primates treated with Galidesivir, compared with 0% for placebo, when treatment began up to 48 hours after infection. Those results are preclinical and come from a specific primate model; the upcoming dose study will need to show whether the effect is consistent enough to inform later studies and regulatory discussions.

FDA pathway narrows the route toward pivotal testing

Island said the US Food and Drug Administration has confirmed that the Animal Rule is an appropriate pathway for developing Galidesivir against Marburg. That route is important because conventional human efficacy trials may be unethical or infeasible for a disease with very high fatality rates. It does not, however, remove the need for an integrated package of animal efficacy, human safety, pharmacokinetic bridging and manufacturing evidence.

The planned sequence calls for a treatment-window study in the first quarter of 2027, followed by a pivotal Marburg study expected to begin around July and produce results by the end of the third quarter, subject to change. Island said the pivotal design will be informed by the first two studies and further FDA feedback. The presentation also states that Galidesivir may qualify for a Tropical Disease Priority Review Voucher if approved, but makes clear that neither approval nor a voucher award is guaranteed.

Uganda program adds a human-data opportunity

Alongside the Marburg work, Island said government and regulatory approvals have been secured to evaluate Galidesivir in Uganda under the World Health Organization’s Monitored Emergency Use of Unregistered and Investigational Interventions framework. Patient treatment is expected to begin in calendar 2027, with clinical, safety and virological data to be collected prospectively. The program is not presented as a conventional controlled efficacy trial, so the usefulness of any resulting data will depend on treatment conditions and the information ultimately generated.

The Uganda approval forms part of the company’s approved Uganda MEURI program, which was previously reported as a route for compassionate Galidesivir use during the Bundibugyo Ebola outbreak. Island is also positioning the program alongside its Marburg Animal Rule strategy, rather than as a replacement for the planned non-human-primate studies.

Cash position sits beside an expanding clinical workload

Island reported $7.83 million in cash at 30 June 2026, with the currency not specified in the presentation, no debt and a potential further $3.2 million from vested options whose exercise prices are below the stated share price. The company said its market capitalisation was $87.35 million as at 16 November, based on 296.1 million shares on issue. Those figures provide financial context, but do not establish how long existing cash will fund the planned studies or whether additional capital will be required.

Manufacturing is another prerequisite. Island said a second GMP manufacturing campaign had been authorised, following the initial Galidesivir GMP campaign reported in October. The presentation also lists an H2 2027 target for preparing a potential New Drug Application covering Marburg and Ebola, while stressing that study outcomes, regulatory interactions, partnerships and government procurement remain conditional.

Bottom Line?

The December dose-response readout is the immediate test of whether Galidesivir’s striking animal data can translate into a defensible dose and a credible pivotal-study design, while the cash balance leaves funding capacity as an important unanswered issue.

Questions in the middle?

  • Will the December dose-response study produce a consistent survival signal across doses and support a clear human-equivalent dose?
  • How much prospective clinical evidence will the Uganda MEURI program generate, and how will regulators use it alongside the Animal Rule package?
  • Can Island fund the treatment-window and pivotal Marburg studies through 2027 without raising additional capital or securing a partner?

Sources